Research. Advocacy. Support.

We advance ovarian cancer research while supporting women and their families.

Learn more about OCRFA

Know Your Risks

About 20 to 25 percent of women diagnosed with ovarian cancer have a hereditary tendency to develop the disease.

Learn about your risks

Latest News

  • Niraparib Approved for Maintenance Treatment of Ovarian Cancer

    (March 28, 2017) The U.S. Food and Drug Administration approved niraparib (ZEJULA, TESARO, Inc.), poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib is the first PARP inhibitor to be approved… More

    Posted
  • Research Updates from 2017 SGO Annual Meeting

    (March 23, 2017) OCRFA staff and volunteers recently attended the Society of Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer, held March 11-14, 2017 in Maryland. Every year women’s cancer physicians and researchers gather at this meeting to discuss the latest in the care and treatment of women with ovarian and other gynecologic cancers. OCRFA… More

    Posted
  • Screening High-Risk Women Catches More Early Stage Ovarian Cancers

    (March 15, 2017) Results from a large study showed that screening for ovarian cancer in high-risk patients led to detection of significantly more early-stage disease as compared with the year after screening ended. However, it is not yet known whether this screening approach would improve survival in screened high-risk women. The results of the study… More

    Posted

Upcoming Events